The European consensus on ulcerative colitis: New horizons?

Gut

Volumn 57, Issue 8, 2008, Pages 1029-1031

  Stange, Eduard F ^a   Travis, Simon P L ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BUDESONIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; TACROLIMUS;

BARIUM ENEMA; CANCER RISK; COLON RESECTION; COLORECTAL CANCER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CROHN DISEASE; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; EUROPE; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MICROBIOLOGICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTITIS; QUESTIONNAIRE; RELAPSE; REMISSION; RESOURCE ALLOCATION; TREATMENT PLANNING; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CONSENSUS; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 48249126370     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.146761     Document Type: Conference Paper

References (13)

1. Stange EF, Travis SPL, Geboes K, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's & Colitis 2008;2:1-23.
2. Travis SPL, Stange EF, Lémann M, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's & Colitis 2008;2:24-62.
3. Biancone L, Michetti P, Travis SPL, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohn's & Colitis 2008;2:63-92.
4. Stange EF, Travis SPL, Vermeire S, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut 2006;55(Suppl 1):i1-15.
5. Travis SPL, Stange EF, Lémann M, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006;55(Suppl 1):i16-35.
6. Caprilli RL, Gassull MA, Escher JC, et al, for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of Crohn's disease: Special situations. Gut 2006;55(Suppl 1):i36-58.
7. Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut 2007;56:161-3.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;ii:1041-8.
10. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763- 86.
11. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-8.
12. Nuding S, Fellermann K, Wehkamp J, et al. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007;56:1240-7.
13. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007;132:576-86.